

Online Data Supplement

Protocol and Rationale for the International Lung Screening Trial (ILST)

Kuan Pin Lim, Henry Marshall, Martin Tammemägi, Fraser Brims, Annette McWilliams, Emily Stone, Renee Manser, Karen Canfell, Marianne Weber, Luke Connelly, Rayleen V Bowman, Ian A Yang, Paul Fogarty, John Mayo, John Yee, Renelle Myers, Sukhinder Atkarkhattra, David CL Lam, Antoni Rosell, Christine D. Berg, Kwun M Fong and Stephen Lam,
On behalf of the International Lung Screening Trial (ILST) Investigators

APPENDIX

Table E1. Study outcomes.

Outcome	Study Aim	Primary or Secondary Outcome
Proportion of individuals selected for screening	1	Primary
Proportion of lung cancers detected	1	Primary
Positive predictive value	1	Primary
Number of individuals sampled by each criteria	1	Secondary
Number of lung cancers detected by each criteria	1	Secondary
Cumulative incidence of lung cancer in PLCO _{m2012} +ve and USPSTF -ve versus PLCO _{m2012} -ve and USPSTF +ve individuals	1	Secondary
Sensitivity, specificity, positive predictive value comparisons between the two criteria when PLCO _{m2012} threshold is set so that the number eligible for screening is the same by either criteria	1	Secondary
Distribution of individuals in each of nodule management groups 1, 2 and 3 <i>Group 1: no or very low risk nodule(s) to be followed by the next regular planned surveillance scan (eg. CAT1 on ILST protocol);</i> <i>Group 2: early recall scan (CATs 2 or 3 on protocol)</i> <i>Group 3: clinical investigation (CATs 4 or 5 on protocol)</i>	2	Primary
Number of lung cancers in each of management groups 1, 2 and 3	2	Secondary
Proportion of lung cancers in each of management groups 1, 2 and 3	2	Secondary